34 results about "Electroretinography" patented technology

A flexible loop electrode for electroretinographic (ERG) recordings of extra-corneal signals with a protective bead and a U-shaped electrode form that is particularly adapted for use with spectacles or a fixed mount. Means also employed to detect electrode integrity.

An ophthalmologic examination apparatus has a main unit housing an illuminating optical system that illuminates a fundus of a subject's eye to be examined and an imaging optical system that images the illuminated eye fundus. First and second attachment units are removably and exchangeably mounted to the main unit for providing different ophthalmologic functions. The first attachment unit houses an imaging device that captures an image of the eye fundus via the imaging optical system housed in the main unit. The second attachment unit houses a light source that emits stimulating light for an electroretinogram and which is projected onto the eye fundus via the imaging optical system housed in the main unit.

In some embodiments, a system for providing a therapeutic treatment to a patient's eye includes a treatment beam source configured to transmit a treatment beam along a treatment beam path. The system further includes a processor coupled to the treatment beam source, the processor being configured to direct the treatment beam onto retinal tissue of the patient's eye and deliver a series of short duration pulses from the treatment beam onto the retinal tissue at a first treatment spot to treat the retinal tissue. In some embodiments, a pre-treatment evaluation method using electroretinography (ERG) data may be used to predict effects of treatment beams at different power values and to determine optimal power values.

The present invention refers to the field of ophthalmology, and in particular to that of devices and methods for supporting the diagnosis of important eye pathologies such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), anomalies and dysfunctions of the retina and of sight in general such as degeneration of the retinal structure of the optical nerve and of the visual cortex. More specifically, the invention concerns a new device and method for recording the electroretinogram (so-called ERG) of an eye, i.e. the bioelectric response of the retina induced by a light stimulus, through the eyelid.

It is intended to provide a novel therapeutic method for a disease with apoptotic degeneration in eye tissue cells such as retinal pigment degeneration. Attention was paid on the concomitant administration of two neurotrophic factors: pigment epithelium-derived factor (PEDF) and fibroblast growth factor 2 (FGF2). The sites of actions are considered to be different between PEDF and FGF2. An SIV-PEDF vector and an SIV-FGF2 vector were constructed and administered to the subretinal space of an RCS rat, which is a disease model of retinal pigment degeneration, and their effects were evaluated. At4 weeks, 8 weeks and 12 weeks after the administration of the vectors, a significantly higher visual cell protection effect was obtained in a group with concomitant administration than in a group with sole administration. Further, the functional evaluation of retina was carried out by electroretinogram and an effect in the group with concomitant administration was significantly higher than in thegroup with sole administration. From the above results, it was found for the first time that the concomitant administration of PEDF and FGF2 has higher effects in the treatment of retinal pigment degeneration than conventional methods.

The invention relates to the technical field of medicaments, in particular to application of tamoxifen in preparation of a medicament for protecting retina photoreceptor cells. According to the application, mouse models with subretinal hemorrhage caused by an autologous blood injection mode are adopted; research shows that the survival rate of the retina photoreceptor cells which are in contact with blood can be improved, the apoptosis rate of the retina photoreceptor cells can be reduced, and the thickness of a retina outer nuclear layer can be maintained by giving the tamoxifen. A protectingeffect on the retina photoreceptor cells can be applied in a protective manner, namely, the tamoxifen is used when new vessels do not burst. Based on experimental results, the protecting effect can also be achieved on surviving retina photoreceptor cells in a retina even after bleeding. The tamoxifen can change an electroretinogram waveform of a normal mouse, which is one of the mechanisms for protecting the retina photoreceptor cells.